Healthcare
Takeda Pharmaceutical Company Limited(TAK)
Live Price
Offline$15.91
+0.25% today
1Y Change
+3.08%
Window
Jun 20, 2025 โ Jun 1, 2026
- Market Cap
- $8.28T
- Revenue Growth
- +7.5%
- EPS Growth
- -25.8%
- Dividend Yield
- 3.8%
Coverage: 238 bars ยท Jun 20, 2025 โ Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Takeda Pharmaceutical Company Limited (TAK) is a Healthcare stock with a market cap of $8.28T and listed on NYSE. The stock last traded around $15.91 and up 3.1% across the available one-year price window (Jun 20, 2025 โ Jun 1, 2026). Baseline metrics include revenue growth of +7.5%, EPS growth of -25.8%, a dividend yield of 3.8%. What stands out right now is revenue +7.5%, EPS -25.8%, free cash flow +263.5% with operating margin 10.3% and ROIC 1.9%. The dividend matters to the case here, with a current yield around 3.8%. Valuation already assumes a fairly strong business story at P/E 73.3 and price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TAK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.5% vs +7.6% peer median
Operating Margin
Below sector median
+10.3% vs +19.4% peer median
P/E
Above sector median
73.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.5% and EPS is at -25.8%, with operating margin around 10.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.8%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.1% | -0.9% | โ |
2026 Jan 29, 2026 | -12.7% | +0.3% | +3.7% | +9.2% |
2025 Oct 30, 2025 | +0.0% | +1.6% | +3.1% | +9.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TAK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TAK Max Drawdown
-19.02%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TAK and SPY.
Company Overview
Takeda Pharmaceutical Company Limited
New York Stock Exchange
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
- Leadership
- Christophe Weber
- IPO Date
- Jan 5, 2010
- Employees
- 49.3k
- Street Address
- 1-1, Nihonbashi-Honcho 2-chome
- Mailing
- Tokyo, 103-8668
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 3278 2111
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 73.3
- EV/EBITDA
- 9.3
- Price/Sales
- 1.9
- Price/Book
- 1.1
Growth
- Revenue
- +7.5%
- EPS
- -25.8%
- Free Cash Flow
- +263.5%
Profitability
- Gross Margin
- 59.5%
- Operating Margin
- 10.3%
- Net Margin
- 2.5%
- ROE
- 1.6%
- ROIC
- 1.9%
Balance Sheet
- Debt/Equity
- 0.64
- Current Ratio
- 1.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.